Amplia is pleased to announce that three patients in the Company’s ACCENT trial, have now recorded a confirmed partial response.
A ‘confirmed partial response’ means there is a minimum 30% decrease in the overall size of tumour lesions in these patients measured over a two-month period.
The ACCENT trial is investigating the use of Amplia’s FAK inhibitor, narmafotinib, in combination with standard-of-care chemotherapy in first-line patients with advanced pancreatic cancer.
The Company recently announced completion of enrolment of the first 26 patients in the trial as part of the industry-standard Simon’s Two-Stage Trial design. A further three confirmed partial or complete responses are now required to complete enrolment of the trial. Once obtained, an additional 24 patients will be enrolled, giving a total of 50 patients for the trial.
Amplia CEO and MD Dr Chris Burns commented:
“To be reporting that three confirmed partial responses have been observed so early in this stage of the trial is extremely encouraging. We are well on track to reach the efficacy threshold of six confirmed partial or complete responses by the end of this quarter, which will then allow us to restart the trial to recruit the full cohort of fifty patients.”
Click here to read the ASX release.
